Prothena (0PT) Q4 2025 Earnings Report

The call conveyed meaningful scientific and business progress — two partner programs advanced to Phase III, strong Phase II biomarker signals (40% reduction in a PD motor endpoint subset; 48% NT‑proBNP reduction for coramitug), introduction of a novel CYTOPE technology with encouraging preclinical TDP‑43 results, and a solid year‑end cash position ($308.4M). Material near‑term upside exists (up to $105M in 2026 milestones and ~ $3B in potential future milestones across partners). Offsetting risks include ARIA‑E safety concerns for PRX012 prompting re‑engineering, some non‑statistically significant secondary endpoints (6‑minute walk test), multi‑year timelines to Phase III primary completions (2029), continued net losses and burn, and reliance on partner decisions for key programs (PRX019). Overall, positives — pipeline advancement, strong partner validation, and a healthy cash balance — outweigh the operational and timing risks.

Prothena's 2026 guidance calls for full‑year net cash used in operating and investing activities of $50–55 million, an estimated net loss of $67–72 million (which includes about $24 million of noncash share‑based compensation), and an expected year‑end cash, cash equivalents and restricted cash balance of approximately $255 million at the midpoint; this guidance does not include up to $105 million of potential aggregate clinical milestone payments from partners in 2026. For context, Prothena closed 2025 with $308.4 million in cash (as of Dec 31, 2025), reported 2025 net cash used in operating and investing activities of $163.7 million (favorable to prior guidance of $170–178 million), a 2025 net loss of $244.1 million (in line with guidance of $240–248 million), had 53.8 million ordinary shares outstanding as of Feb 12, 2026, and a simple capital structure with zero debt.